[ad_1]
k10012608481_202009091216_202009091217.mp4
British pharmaceutical giant Astra Zeneca has announced that it has temporarily suspended clinical trials of a new coronavirus vaccine that is being developed with the University of Oxford. Details are not disclosed, but it is said to be to verify security data.
The statement read: “This is because an independent committee will verify the safety data.” “In large-scale clinical trials, trial participants may have some symptoms, so independent verification is required. I need to.”
On the other hand, details such as what type of symptoms occurred have not been clarified.
AstraZeneca states: “We will give due consideration to the safety of test participants while minimizing the impact on the development program.”
The development of vaccines for the new coronavirus is ongoing in countries like China and the United States, but the vaccine being developed by AstraZeneca and the University of Oxford is one of the most advanced.
The Japanese government has basically agreed that if AstraZeneca is developed successfully, it will receive 120 million doses from the beginning of next year and 60 million people with two doses.
On the other hand, the development of new vaccines against the coronavirus is advancing at an unprecedented speed, as each country rushes to implement it and experts call for a comprehensive verification of its safety.
Secretary General Suga “Appropriate judgment of approval”
At a press conference in the morning, Secretary of State Suga said: “We have received reports that the Ministry of Health, Labor and Social Welfare is collecting detailed information from the companies. We will ensure the amount of vaccines that can be provided to all people by the first half of next year. In order to achieve this, if an approval application is submitted in Japan, we will make the appropriate decision on whether or not to approve it from the perspective of ensuring efficacy and safety, based on data from clinical trials and the latest scientific knowledge “. Said.
